A perspective on the evolution of management of cancer- and chemotherapy-induced anemia

JNCCN Journal of the National Comprehensive Cancer Network

Volumn 10, Issue 4, 2012, Pages 434-437

  Rodgers, George M ^a,b  

^a UNIVERSITY OF UTAH SCHOOL OF MEDICINE   (United States)

^b AMGEN INC   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ANTIANEMIC AGENT; ANTINEOPLASTIC AGENT; FERRITIN; HEMOGLOBIN; IRON; NOVEL ERYTHROPOIESIS STIMULATING PROTEIN;

ANEMIA; CANCER CHEMOTHERAPY; CHEMOTHERAPY INDUCED ANEMIA; DRUG EFFICACY; DRUG INDICATION; DRUG SAFETY; ERYTHROCYTE TRANSFUSION; FERRITIN BLOOD LEVEL; HEMOGLOBIN BLOOD LEVEL; HUMAN; IRON DEFICIENCY; IRON THERAPY; PRACTICE GUIDELINE; SHORT SURVEY; SURVIVAL RATE;

EID: 84860705210     PISSN: 15401405     EISSN: 15401413     Source Type: Journal    
DOI: 10.6004/jnccn.2012.0044     Document Type: Short Survey

References (12)

1. Henke M, Laszig R, Rube C, et al. Erythropoietin to treat head and neck cancer patients with anaemia undergoing radiotherapy: randomised, double-blind, placebo-controlled trial. Lancet 2003;362:1255-1260. (Pubitemid 37324251)
2. Bohlius J, Langensiepen S, Schwarzer G, et al. Erythropoietin for patients with malignant disease. Cochrane Database Syst Rev 2004;3:CD003407.
3. Leyland-Jones B for the BEST Investigators and Study Group. Breast cancer trial with erythropoietin terminated unexpectedly. Lancet Oncol 2003;4:459-460.
4. Auerbach M, Ballard H, Trout JR, et al. Intravenous iron optimizes the response to recombinant human erythropoietin in cancer patients with chemotherapy-related anemia. J Clin Oncol 2004;22:1301-1307. (Pubitemid 41079845)
5. Bohlius J, Langensiepen S, Schwarzer G, et al. Recombinant human erythropoietin and overall survival in cancer patients; results of a comprehensive meta-analysis. J Natl Cancer Inst 2005;6:489-498. (Pubitemid 40590430)
6. Bohlius J, Wilson J, Seidenfeld J, et al. Recombinant human erythropoietins and cancer patients: updated meta-analysis of 57 studies including 9353 patients. J Natl Cancer Inst 2006;17:708-714. (Pubitemid 43821788)
7. Khorana AK, Francis CW, Blumberg N, et al. Blood transfusions, thrombosis, and mortality in hospitalized patients with cancer. Arch Intern Med 2008;168:2377-2381.
8. Henry DH, Dahl NV, Auerbach M, et al. Intravenous ferric gluconate significantly improves response to epoetin alfa versus oral iron or no iron in anemic patients with cancer receiving chemotherapy. Oncologist 2007;12:231-242.
9. Bohlius J, Schmidin K, Brillant C, et al. Erythropoietin or darbepoetin for patients with cancer-meta-analysis based on individual patient data. Cochrane Database Syst Rev 2009;3:CD007303.
10. Glaspy J, Crawford J, Vansteenkiste J, et al. Erythropoiesis-stimulating agents in oncology: a study-level meta-analysis of survival and other safety outcomes. Br J Cancer 2010;102:301-315.
11. Gilreath JA, Sageser DS, Jorgenson JA, Rodgers GM. Establishing an anemia clinic for optimal erythropoietic-stimulating agent use in hematology-oncology patients. J Natl Compr Canc Netw 2008;6:577-584. (Pubitemid 352007765)
12. Gilreath JA, Stenehjem DD, Rodgers GM. Total dose iron dextran infusion in cancer patients: is it saFe2+? J Natl Compr Canc Netw 2012;10: in press.